Gilead Sciences Valuation
Is GILD undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GILD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GILD (€85.02) is trading below our estimate of fair value (€221.89)
Significantly Below Fair Value: GILD is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GILD?
Key metric: As GILD is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is GILD's PS Ratio? | |
|---|---|
| PS Ratio | 4x |
| Sales | US$28.30b |
| Market Cap | US$110.46b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.5x |
| Enterprise Value/EBITDA | 9.1x |
| PEG Ratio | 21.7x |
Price to Sales Ratio vs Peers
How does GILD's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.8x | ||
VRTX Vertex Pharmaceuticals | 10.9x | 8.7% | US$116.2b |
REGN Regeneron Pharmaceuticals | 5.8x | 6.8% | US$80.0b |
AMGN Amgen | 4.8x | 2.5% | US$154.7b |
CSL CSL | 5.9x | 6.5% | AU$132.5b |
GILD Gilead Sciences | 4x | 2.4% | €110.5b |
Price-To-Sales vs Peers: GILD is good value based on its Price-To-Sales Ratio (4x) compared to the peer average (6.8x).
Price to Sales Ratio vs Industry
How does GILD's PS Ratio compare vs other companies in the European Biotechs Industry?
| 38 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 38 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: GILD is good value based on its Price-To-Sales Ratio (4x) compared to the European Biotechs industry average (7.9x).
Price to Sales Ratio vs Fair Ratio
What is GILD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate GILD's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €85.02 | €91.48 +7.6% | 12.9% | €117.98 | €65.12 | n/a | 28 |
| Nov ’25 | €82.35 | €81.31 -1.3% | 13.9% | €113.74 | €63.80 | n/a | 28 |
| Oct ’25 | €75.19 | €75.83 +0.9% | 14.1% | €108.02 | €62.18 | n/a | 27 |
| Sep ’25 | €71.32 | €75.06 +5.2% | 14.1% | €107.06 | €61.63 | n/a | 27 |
| Aug ’25 | €71.19 | €76.00 +6.8% | 15.1% | €109.67 | €61.75 | n/a | 27 |
| Jul ’25 | €64.37 | €77.42 +20.3% | 14.2% | €111.04 | €62.52 | n/a | 26 |
| Jun ’25 | €58.30 | €76.23 +30.8% | 14.0% | €107.85 | €61.76 | n/a | 26 |
| May ’25 | €60.99 | €78.28 +28.3% | 13.0% | €109.43 | €64.54 | n/a | 27 |
| Apr ’25 | €68.04 | €79.40 +16.7% | 12.6% | €111.14 | €63.38 | n/a | 26 |
| Mar ’25 | €66.92 | €81.29 +21.5% | 12.5% | €111.95 | €63.84 | n/a | 27 |
| Feb ’25 | €71.82 | €82.88 +15.4% | 11.9% | €106.86 | €63.56 | n/a | 27 |
| Jan ’25 | €73.46 | €81.66 +11.2% | 11.9% | €105.07 | €62.50 | n/a | 27 |
| Dec ’24 | €70.50 | €83.36 +18.2% | 11.7% | €106.98 | €65.48 | n/a | 27 |
| Nov ’24 | €75.52 | €85.69 +13.5% | 11.2% | €109.30 | €66.90 | €82.35 | 26 |
| Oct ’24 | €71.40 | €85.52 +19.8% | 10.8% | €108.62 | €66.48 | €75.19 | 26 |
| Sep ’24 | €71.06 | €84.10 +18.3% | 10.3% | €106.33 | €73.33 | €71.32 | 24 |
| Aug ’24 | €68.58 | €82.84 +20.8% | 10.1% | €103.96 | €69.61 | €71.19 | 25 |
| Jul ’24 | €70.18 | €85.53 +21.9% | 9.8% | €106.21 | €71.12 | €64.37 | 25 |
| Jun ’24 | €71.28 | €86.31 +21.1% | 9.8% | €107.20 | €71.78 | €58.30 | 25 |
| May ’24 | €73.50 | €84.00 +14.3% | 8.8% | €104.36 | €72.60 | €60.99 | 25 |
| Apr ’24 | €75.43 | €85.95 +13.9% | 9.7% | €108.34 | €72.54 | €68.04 | 22 |
| Mar ’24 | €74.53 | €86.19 +15.6% | 10.4% | €107.54 | €72.00 | €66.92 | 23 |
| Feb ’24 | €76.25 | €80.86 +6.0% | 12.4% | €102.33 | €58.08 | €71.82 | 24 |
| Jan ’24 | €79.44 | €79.86 +0.5% | 13.0% | €98.89 | €59.33 | €73.46 | 24 |
| Dec ’23 | €84.15 | €78.14 -7.1% | 12.2% | €99.75 | €59.85 | €70.50 | 24 |
| Nov ’23 | €80.35 | €79.59 -0.9% | 12.9% | €99.22 | €63.78 | €75.52 | 24 |
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
ALM
€8.22
7D
-3.5%
1Y
-1.4%
Teva Pharmaceutical Industries
US$19.3b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$16.30
7D
2.5%
1Y
88.7%
H. Lundbeck
DKK 43.0b
A biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
LUNB
DKK 6.04
7D
0.2%
1Y
35.3%